Opioid agonist treatment initiation and linkage for hospitalized patients seen by a substance use disorder consultation service

Background: Facilitating opioid agonist treatment (OAT) for opioid use disorder (OUD) is an important role of hospital substance use disorder (SUD) consultation services. In the NavSTAR trial, hospital patients receiving SUD consultation who were randomly assigned to patient navigation services for 3 months post-discharge had fewer readmissions compared to usual care. Methods: This secondary analysis examined hospital-based OAT initiation (pre-randomization) and community-based OAT linkage (post-discharge) among NavSTAR trial participants with OUD (N= 314). Associations between OAT initiation and linkage, and patient demographics, housing status, comorbid SUD diagnoses, recent substance use, and study condition were examined using multinomial and dichotomous logistic regression. Results: Overall, 57.6% initiated OAT during hospitalization (36.3% methadone, 21.3% buprenorphine). Compared to participants not initiating OAT, participants who received methadone were more likely to be female (Relative Risk Ratio [RRR]= 2.05, 95% CI= 1.11, 3.82, p= 0.02), while participants who received buprenorphine were more likely to report homelessness (RRR= 2.57, 95% CI= 1.24, 5.32, p= 0.01). Compared to participants initiating methadone, participants initiating buprenorphine were more likely to be non-White (RRR= 3.89; 95% CI= 1.55, 9.70; p= 0.004) and to report prior buprenorphine treatment (RRR= 2.57; 95% CI= 1.27, 5.20; p= 0.009). OAT linkage within 30-days post-discharge was associated with hospital-based buprenorphine initiation (Adjusted Odds Ratio [AOR]= 3.86, 95% CI= 1.73, 8.61, p= 0.001) and patient navigation intervention (AOR= 2.97, 95% CI= 1.60, 5.52, p= 0.001). Conclusions: OAT initiation differed by sex, race, and housing status. Hospital-based OAT initiation and patient navigation were independently associated with linkage to community-based OAT. Hospitalization is a reachable moment to begin OAT to alleviate withdrawal and facilitate treatment continuity post-discharge.